• New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively
  • Enrollment in X-NOVA2 study in MDD completed with approximately 360 total patients; topline data readout expected Q1 2027
  • The Company has voluntarily initiated a temporary pause of enrollment of new patients in ongoing psychiatry studies; patients currently enrolled in the ongoing studies remain active
  • Conference call today at 4:30 pm ET

VANCOUVER, BC and BOSTON, MA, Sept. 17, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it has submitted a New Drug Application (NDA) for azetukalner in focal seizures (FS) to the U.S. Food and Drug Administration (FDA).

The NDA submission is based on positive clinical data from two global, randomized, double-blind, placebo-controlled trials for azetukalner in focal seizures, including the Phase 2b X-TOLE study and Phase 3 X-TOLE2 study. Across the two studies, treatment with all four doses of azetukalner demonstrated a statistically significant reduction from baseline in monthly seizure frequency compared with placebo, and azetukalner was generally well-tolerated with a consistent safety profile observed in both studies. These safety results are comparable with the long-term safety observed in the X-TOLE open label extension (OLE) study, with the entire epilepsy program generating more than 1,500 patient-years of safety and exposure data.

“We are very pleased to announce completion of the NDA submission for azetukalner in focal seizures in epilepsy. Azetukalner has the potential to deliver much needed innovation to treat people living with focal seizures, with strong efficacy, a differentiated mechanism of action that may enable rational polytherapy, once-daily dosing with no dose adjustments for other antiseizure medications, and a consistent and generally well-tolerated safety profile,” said Ian Mortimer, President and CEO of Xenon. “This is a significant milestone for Xenon as we continue to work toward the potential of our first approval and launch and becoming a fully integrated neuroscience company.”

The ongoing Phase 3 X-TOLE3 and X-ACKT studies of azetukalner in focal seizures and primary generalized tonic-clonic seizures (PGTCS), respectively, continue to enroll patients to support expansion of use across seizure types and global regions.

In addition, the Company announced today that it has implemented a voluntary pause on enrollment for new patients in its ongoing clinical studies in major depressive disorder (MDD) and bipolar depression (BPD), following an analysis of neuropsychiatric adverse events in these studies. Participants currently enrolled in the randomized controlled psychiatry studies and associated OLE studies will continue on study. The observed events, the rate of these events and their severity, are consistent with the known safety and tolerability profile of azetukalner and its mechanism; however, such adverse events had not previously been seen in the Phase 2 X‑NOVA clinical study in MDD. The enrollment pause is being implemented as a precautionary measure by Xenon in consultation with its Data Safety Monitoring Board (DSMB) and is expected to be temporary. Xenon is working to evaluate potential dosing modifications to help mitigate these adverse events. This voluntary action does not impact ongoing epilepsy studies.

X-NOVA2 enrollment has reached approximately 80% of its initial target of 450 patients, which is sufficiently powered to demonstrate a clinically meaningful change in the study’s primary endpoint of HAM-D17. The Company plans to complete the six-week dosing period for patients currently enrolled in the trial and unblind the data. Topline data for X-NOVA2 are now expected in Q1 2027.

“We remain very confident in the product profile of azetukalner as a potential new treatment option for patients with epilepsy based on strong efficacy and safety data and a consistent safety profile across over 1,500 patient-years of data,” said Chris Kenney, Chief Medical Officer of Xenon. “For potential expansion in psychiatry, we would like to evaluate whether modifying the dose regimen may help enhance azetukalner’s tolerability profile in this indication. Completing the X-NOVA2 study will help assess the efficacy and tolerability of azetukalner in MDD, which will provide important data to guide us in the future clinical development in psychiatry indications.”

Conference Call Information

Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the azetukalner NDA submission and provide an update on the psychiatry clinical programs. A listen-only webcast can be accessed on the Investors section of the Xenon website, with a replay available following the event. Participants can access the conference call by dialing (800) 715-9871 or (646) 307-1963 for international callers and referencing conference ID 8451337.

About Azetukalner
Azetukalner is a novel, potent KV7 potassium channel opener currently in development for the treatment of epilepsy, major depressive disorder and bipolar depression. It represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development. Azetukalner is designed to open potassium channels in the central nervous system, allowing potassium ions to flow and hyperpolarizing neurons. This process helps reduce excessive neuronal firing, which is a key contributor to several neurologic and psychiatric disorders.

About Epilepsy and Focal Seizures
Epilepsy is a neurological condition characterized by abnormal electrical activity in the brain that leads to spontaneous, recurrent and unprovoked seizures. It is the fourth most common neurological condition and affects approximately three million adults in the U.S. Focal epilepsy is the most common form of epilepsy. It is characterized by recurrent seizures that originate in a specific area of the brain (focal seizures), leading to various motor, sensory, autonomic, or cognitive symptoms depending on the affected region.

Epilepsy is often managed with polytherapy – or concurrent use of multiple antiseizure medications (ASMs) – to improve seizure control. However, despite more than 30 available epilepsy treatments, up to half of people with focal epilepsy still live with uncontrolled seizures. Epilepsy treatment is further complicated by often burdensome drug interactions and lengthy titration and dose-adjustment periods. These challenges highlight the critical need for a new therapeutic approach.

Phase 3 Epilepsy Studies
The clinical development program for azetukalner in epilepsy includes three Phase 3 clinical studies in focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). The completed X-TOLE2 study and the ongoing X-TOLE3 study were both designed as multicenter, randomized, double-blind, placebo-controlled studies to evaluate the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients per study with FOS. The primary efficacy endpoint is median percent change (MPC) in monthly seizure frequency from baseline through the 12-week double-blind period (DBP) of azetukalner compared to placebo.

X-ACKT is a multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of 25 mg of azetukalner administered with food as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is MPC in monthly PGTCS frequency from baseline through the 12-week DBP of azetukalner compared to placebo. Upon completion of the DBP in the Phase 3 epilepsy studies, eligible patients may enter an open-label extension (OLE) study for up to six years.

Phase 3 MDD & BPD Studies
The Phase 3 X-NOVA major depressive disorder (MDD) program includes three multicenter, randomized, double-blind, placebo-controlled clinical studies to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 450 patients per study with moderate-to-severe MDD. The primary efficacy endpoint is the change from baseline in the HAM-D17 score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an open-label extension (OLE) study for up to 12 months.

The Phase 3 X-CEED Bipolar Depression (BPD) program includes two multicenter, randomized, double-blind, placebo-controlled clinical studies to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 400 patients per study with BPD I or II. The primary efficacy endpoint is the change from baseline in the MADRS score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an open-label extension (OLE) study for up to 12 months.

About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the status of, and potential results from, clinical studies; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical study designs; our ability to achieve milestones in our pipeline and development programs, including the completion of trial enrollment and timing of topline data readout from any clinical studies; the timing and results of our interactions with regulators; and our ability to successfully develop, obtain regulatory approval for, and commercialize azetukalner and our other product candidates. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical studies may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical study results may not be replicated in later clinical studies; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may delay the initiation or completion of clinical studies or impose additional requirements prior to approval; the impact of market, industry, and regulatory conditions on clinical study enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

For Investors:
Laura Perry/Emily Huang
Argot Partners
Xenon@argotpartners.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com

ABU DHABI, United Arab Emirates, Sept. 17, 2026 (GLOBE NEWSWIRE) — NIP Group Inc. (“NIP Group” or the “Company”) (NASDAQ: NIPG), a leading digital entertainment company, today announced that it will hold an extraordinary general meeting of shareholders (the “EGM”) at 8:00 p.m., Hong Kong time, on October 16, 2026 at 29/F, Entertainment Building, 30 Queen’s Road Central, Central, Hong Kong.

The purpose of the EGM is for the Company’s shareholders to consider and, if thought fit, pass each of the proposed resolutions set forth in the notice of the EGM (the “EGM Notice”). The EGM Notice, which contains detailed proposals and additional information regarding the EGM, and the form of proxy for the EGM are available on the Company’s website at https://ir.nipg.com/. The board of directors of the Company fully supports the proposed resolutions set out in the EGM Notice and recommends that shareholders and holders of the Company’s American depositary shares (“ADSs”) vote in favor of these resolutions.

The board of directors of the Company has fixed the close of business on September 17, 2026 (Eastern time) as the record date (the “Record Date”) for determining the shareholders entitled to receive notice of, and to vote at, the EGM or any adjourned or postponed meeting thereof. Holders of record of the Company’s ordinary shares at the close of business on the Record Date are entitled to attend and to vote at the EGM and any adjourned or postponed meeting thereof. Holders of record of the Company’s ADSs representing the Company’s Class A ordinary shares at the close of business on the Record Date who wish to exercise their voting rights for the underlying Class A ordinary shares must act through Citibank, N.A., the depositary of the Company’s ADS program.

Shareholders and ADS holders may access the Company’s public filings free of charge at the Company’s investor relations website https://ir.nipg.com/, and on the SEC’s website www.sec.gov.

About NIP Group
NIP Group (NASDAQ: NIPG) operates at the nexus of Bitcoin mining, compute infrastructure and global digital entertainment. Rooted in a decade of gaming DNA and industry leadership, the Company brings a cultural and community-driven edge to digital asset operations. Headquartered in Abu Dhabi with teams worldwide, NIP Group pairs significant compute capacity with a global gaming and entertainment ecosystem including esports teams, live events and content networks, reaching hundreds of millions of fans.

Safe Harbor Statements
This press release contains statements that constitute “forward-looking” statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” or other similar expressions. Among other things, the business outlook and quotations from management in this press release, as well as NIP Group’s strategic and operational plans, contain forward-looking statements. NIP Group may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about NIP Group’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NIP Group’s growth strategies; its future business development, results of operations and financial condition; its ability to maintain and enhance the recognition and reputation of its brand; developments in the relevant governmental laws, regulations, policies toward NIP Group’s industry; and general economic and business conditions globally and in the countries or regions where NIP Group has operations; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in NIP Group’s filings with the SEC. All information provided in this press release is as of the date of this press release, and NIP Group undertakes no obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:
NIP Group Inc.
Investor Relations: ir@nipgroup.gg
Public Relations: pr@nipgroup.gg

Power-dense permanent magnet propulsion motors and advanced variable-frequency drives will power the Republic of Korea Navy’s first full-electric-drive surface combatant

ARLINGTON, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) — Leonardo DRS, Inc. (Nasdaq: DRS) announced today that it has entered into a contract with Doosan Enerbility to provide the electric propulsion system for the Republic of Korea Navy’s KDDX destroyer program, the lead ship of which is being built by Hanwha Ocean. KDDX is a next-generation guided-missile destroyer, considered a cornerstone of South Korea’s future naval fleet requirements. The program is expected to deliver at least six destroyers and represents South Korea’s first indigenously designed and built destroyer program.

Under the award, DRS will supply an integrated electric power and propulsion solution featuring its power-dense 100-Series permanent magnet propulsion motors and matched high-performance, compact variable frequency drives. The system is designed to provide efficient, reliable propulsion in a compact configuration for next-generation naval platforms

Doosan Enerbility and DRS will collaborate on the destroyer’s integrated power and propulsion system, which includes electrical and mechanical equipment extending from the prime movers to the propellers.

The KDDX program is expected to introduce the Republic of Korea Navy’s first full-electric-drive surface combatants, as part of a planned class of next-generation destroyers designed to meet the demanding multi-mission requirements of a modern blue-water fleet. As navies worldwide move toward integrated electric propulsion to support advanced sensors, weapons and mission systems, the KDDX program represents a significant milestone in the adoption of full electric drive for front-line surface combatants.

“Modern naval platforms require electric power and propulsion systems that can meet current operational demands while providing the flexibility to support future mission needs,” said John Baylouny, president and chief executive officer of Leonardo DRS. “Our advanced electric-propulsion technologies are designed to deliver the power capacity, efficiency, reliability and adaptability required for advanced radars, advanced EW systems, directed energy systems, the charging of unmanned vehicles, the launch of drone swarms and other increasingly power-intensive mission capabilities.”

“DRS is proud to support the Republic of Korea Navy’s KDDX destroyer program with proven electric propulsion technology,” said Jon Miller, senior vice president and general manager of Naval Power Systems at Leonardo DRS. “For more than a decade our systems have supported Republic of Korea Navy FFX II/III/IV frigates, and we have demonstrated the ability to scale our electric-propulsion technology for the most demanding naval applications, including the COLUMBIA-class submarine program. This technology is designed to support efficient propulsion, compact installation and the electrical demands of advanced shipboard systems. We look forward to working with Doosan Enerbility and Hanwha Ocean in support of this important program.”

The DRS permanent magnet motor technology is designed to provide high torque density in a compact architecture, helping reduce size and weight compared with conventional electric machines. Paired with the company’s variable-frequency drive, the system delivers precise, and highly efficient propulsion control while reducing engine-room footprint and supporting greater flexibility in ship design. The system is designed, built, and delivered by DRS to meet applicable military requirements for power quality, shock, and vibration, as well as Republic of Korea Navy operational requirements.

This selection builds on a long record of DRS electric propulsion success with the Republic of Korea Navy, including hybrid electric drive systems provided for the 20 anti-submarine warfare frigates in the FFX Batch II, III and IV frigate programs. DRS is a leading provider of next-generation electric power and propulsion technology for the U.S. Navy and allied navies worldwide. The KDDX program reinforces the company’s role as a trusted provider of integrated electric drive solutions for the world’s most advanced naval platforms.

About Leonardo DRS

Leonardo DRS, Inc. (Nasdaq: DRS) is at the forefront of developing transformative defense technologies using its proven agility and delivering innovative solutions for U.S. national security customers and allies worldwide. We specialize in rapidly providing high-performance, multi-domain capabilities across next-generation advanced sensing, network computing, force protection, and electric power and propulsion. Our reputation as a trusted provider is built on a continuous focus on practical innovation, delivering quality, and meeting our customers’ most demanding mission requirements. For further information on our complete range of capabilities, visit www.LeonardoDRS.com.

Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Those statements reflect current expectations, assumptions and estimates of future performance and economic conditions. The company cautions investors that any forward-looking statements which include contract values, contract performance and our development and production of products are subject to risks and uncertainties that may cause actual results and future trends to differ materially from those matters expressed in or implied by such forward-looking statements.

Leonardo DRS Investor Relations Contact
Camilla Yanushevsky
Director, Investor Relations
+1 571 309 8216
investorrelations@drs.com

Leonardo DRS Media Contact
Charles Jones
Director, Marketing and Corporate Communications
+1 571-737-8800
charles.jones@drs.com  

DALLAS, Sept. 17, 2026 (GLOBE NEWSWIRE) — Capital Southwest Corporation (“Capital Southwest”) (Nasdaq: CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, today announced that the U.S. Small Business Administration (the “SBA”) has approved Capital Southwest SBIC II, LP’s (“SBIC II”) request to increase its leverage commitment from $175 million to $250 million pursuant to recent legislation.

The increased leverage capacity enhances Capital Southwest’s ability to continue deploying capital through SBIC II, a wholly owned subsidiary of Capital Southwest, in support of its lower middle market investment strategy. SBIC II expects to use the additional capacity to pursue SBIC-eligible investment opportunities consistent with the investment strategy approved at licensure, while maintaining its existing underwriting standards and portfolio diversification approach. The SBA may limit the amount that may be drawn each year under the leverage commitment, and each issuance of leverage is conditioned on SBIC II’s full compliance, as determined by the SBA, with the terms and conditions set forth in the SBA regulations.

The SBA program has played a pivotal role within Capital Southwest’s lower middle market investment strategy since receiving its first SBIC license in April 2021. Capital Southwest received an exemptive order from the Securities and Exchange Commission that allows for the exclusion of SBA-guaranteed debentures from the definition of senior securities in the asset coverage requirement applicable to the Company under the Investment Company Act of 1940, as amended.

About Capital Southwest

Capital Southwest Corporation (Nasdaq: CSWC) is a Dallas, Texas-based, internally managed business development company with approximately $2.2 billion in investments at fair value as of June 30, 2026. Capital Southwest is a middle market lending firm focused on supporting the acquisition and growth of middle market businesses with $5 million to $50 million investments across the capital structure, including first lien, second lien and non-control equity co-investments. As a public company with a permanent capital base, Capital Southwest has the flexibility to be creative in its financing solutions and to invest to support the growth of its portfolio companies over long periods of time.

Investor Relations Contact:

Michael S. Sarner, President and Chief Executive Officer
214-884-3829

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2026 it granted stock options to purchase an aggregate of 52,834 shares of common stock and 35,025 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 23 employees, whose employment commenced in August and September 2026 as a material inducement to their employment.

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of $69.31 per share, which is equal to the closing price of the Company’s common stock on September 15, 2026 and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company’s Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer 

Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlined in Cytokinetics’ filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S. and the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo syndrome Type A

Ultragenyx’s UltraCare® program will support access, and commercial product is expected to be available to ship to Qualified Treatment Centers within 30-60 days

FAYUVI marks the second gene therapy approval, and sixth FDA approval overall, for Ultragenyx

The Company received a Priority Review Voucher upon FAYUVI approval

Ultragenyx to Host Conference Call on September 17, 2026 at 5:30 p.m. Eastern Time

NOVATO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) granted standard full approval of FAYUVI™ (rebisufligene etisparvovec-hopf), also known as UX111, for the treatment of pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A). FAYUVI is the first-ever FDA-approved treatment for Sanfilippo syndrome Type A, a progressive and fatal neurodegenerative disease, and the second gene therapy approval for Ultragenyx. The Company received a Priority Review Voucher upon this approval.

“The approval of FAYUVI reflects years of research from scientists and developers, as well as unwavering support from so many families and patient organizations in the face of a devastating, universally fatal disease with no treatment options. This is a historic milestone for a community that has waited far too long, but has never given up hope,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “We recognize the profound urgency of making this therapy available to families, and our focus now is on supporting timely access in the U.S. as we work closely with treatment centers and payers to support families on the gene therapy treatment journey. FDA approval is an important first step toward our long-term goal to bring this treatment option to families of children with Sanfilippo syndrome Type A around the world.”

“The U.S. FDA approval of FAYUVI is a milestone that the Sanfilippo syndrome Type A community spent decades fighting to achieve: the first-ever treatment for a disease that relentlessly steals a child’s abilities, independence, and future,” said Glenn O’Neill, president and co-founder of the Cure Sanfilippo Foundation, and Terri Klein, CNPM, MPA, president and chief executive officer of the National MPS Society. “This remarkable scientific achievement is the culmination of decades of advocacy, fundraising, collaboration, and perseverance across the Sanfilippo community along with researchers, clinicians, and industry partners who never lost faith that progress was possible. We celebrate by honoring every family who contributed and remembering the children we lost while waiting for this day. Together, we look ahead with renewed hope knowing that this treatment is now approved for children and families affected by this heartbreaking disease.”

About Sanfilippo Syndrome Type A and FAYUVI
Sanfilippo syndrome Type A is an ultra-rare, fatal lysosomal storage disease that primarily affects the brain and is marked by rapid, progressive neurodegeneration beginning in early childhood. Children with Sanfilippo syndrome Type A typically experience progressive global developmental delay, followed by the loss of cognitive, language, and motor function, ultimately leading to early death. Sanfilippo syndrome Type A is estimated to affect approximately 3,000 to 5,000 patients in commercially accessible geographies, with a median life expectancy of 15 years. The disease is caused by a deficiency of the sulfamidase (SGSH) enzyme, which results in the accumulation of heparan sulfate substrate in cells and progressive damage to the central nervous system. FAYUVI is a single-dose intravenous AAV9 gene therapy designed to deliver a functional copy of the deficient enzyme gene that can express and replace the SGSH enzyme.

“This gene therapy addresses a pressing unmet clinical need and offers families a promising therapeutic option,” said Kevin M. Flanigan, M.D., director of the Center for Gene Therapy at Nationwide Children’s Hospital and principal investigator on the study that led to its approval. “It is additionally gratifying in that this vector was first developed at Nationwide Children’s more than a decade ago, and its approval highlights our commitment to developing therapies that meaningfully impact children’s health.”

The final delivery of this therapy did not come without tremendous difficulties during its development, and the Company hopes this approval will revitalize the investment in other ultra-rare gene therapies. The therapy was developed by Haiyan Fu, PhD, and Doug McCarty, PhD, during their tenures at Ohio State University/Nationwide Children’s Hospital and was licensed to Abeona. When funding constraints arose despite positive clinical data, Abeona made the pivotal decision to out-license the asset to Ultragenyx, ensuring this vital treatment reached the finish line for patients. Ultragenyx thanks the researchers, the development and leadership team at Abeona, and so many families, patient advocacy groups, and investigators who worked tirelessly through so many obstacles over the many years to lead the Company to this moment of shared success.

Clinical Program Supporting FAYUVI
The approval of FAYUVI is supported by data from the pivotal Transpher A trial and long-term follow-up studies, which demonstrated clinical benefit relative to the decline observed in natural history, along with durable treatment effect across clinical assessments and multiple biomarkers while maintaining an acceptable safety profile. Clinical data now extend to up to nearly 8 years of follow-up.

Biochemical efficacy in replacing the missing enzyme was demonstrated by a reduction in accumulated cerebral spinal fluid (CSF) heparan sulfate (HS) levels throughout the study and across all age groups. Clinical efficacy was assessed based on patients’ mean change in Bayley-III Cognitive raw score from 24 to 60 months of age. FAYUVI-treated patients from the modified intention-to-treat (mITT) population (N=17) were compared to untreated patients with Sanfilippo syndrome Type A from an external, comparable natural history cohort (N=27). FAYUVI-treated patients (mITT) demonstrated a 23.5 point higher (p<0.0001) cognitive score over natural history during the period of study, providing the efficacy basis for standard full approval.

Enabling Access for Eligible Patients
Ultragenyx will provide support to help enrolled patients and caregivers navigate access to treatment through its UltraCare® program, which now includes specially trained UltraCare® Gene Therapy Guides to help understand insurance coverage, assist in obtaining treatment support, and answer questions about the treatment process. Dedicated in-house UltraCare Gene Therapy Guides are available Monday through Friday from 9 a.m. to 8 p.m. Eastern Time at 888-756-8657. More information is available at www.ultracaresupport.com. 

FAYUVI will be available through a network of Qualified Treatment Centers (QTCs), which are U.S.-based healthcare institutions with specialized expertise and training to administer gene therapy. Ultragenyx expects commercial product will be available for shipment to QTCs within 30-60 days.

FAYUVI is manufactured entirely within the U.S., at Ultragenyx’s Gene Therapy Manufacturing Facility in Bedford, Massachusetts, and Andelyn Biosciences in Columbus, Ohio.

Additional details, including information on the QTC network, will be available on fayuvi.com, which is expected to be live within the coming days.

Investor Conference Call
Ultragenyx will host a conference call today at 5:30 p.m. Eastern Time/2:30 p.m. Pacific Time to discuss the FAYUVI approval. The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations.

INDICATION
FAYUVI™ (rebisufligene etisparvovec-hopf) is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome type A) in pediatric patients with preserved neurodevelopmental function.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hepatotoxicity
Elevated liver enzymes (ALT, AST, and GGT) were observed in clinical studies of FAYUVI. Prior to FAYUVI infusion, assess liver function by clinical examination and laboratory testing (ALT, AST, GGT, and total bilirubin), and evaluate liver-related medical history. Administer corticosteroids to all patients before and after the FAYUVI infusion. If abnormalities are observed, adjust the corticosteroid treatment regimen, including increasing the dose and/or prolonging the corticosteroid taper period.

Closely monitor ALT, AST, GGT, and total bilirubin levels after FAYUVI administration until 2 weeks after the corticosteroid taper is complete and as clinically indicated. Continue to monitor liver function in all patients who develop elevated liver enzymes until levels return to baseline. 

Thrombocytopenia
Decreased platelet counts were observed in clinical studies of FAYUVI.
Prior to FAYUVI infusion, assess platelet counts. Monitor platelet counts weekly for the first 4 weeks, then monthly for 6 months following infusion. Continue monitoring as clinically indicated.

Thrombotic Microangiopathy
Thrombotic microangiopathy (TMA) has been reported in association with AAV gene therapies. While there have been no cases of TMA associated with FAYUVI in clinical studies, laboratory and clinical monitoring for TMA following FAYUVI infusion is recommended.

Monitor platelet counts closely within the first 4 weeks following FAYUVI infusion. Signs and symptoms of TMA may include, but are not limited to, thrombocytopenia, hemolytic anemia, easy bruising, hypertension, seizures, decreased urine output, and renal dysfunction. If TMA is suspected, immediately consult a pediatric hematologist and/or nephrologist for further evaluation and management as clinically indicated.

Hypersensitivity and Infusion Reactions
Infusion reactions, including hypersensitivity reactions and anaphylaxis, may occur with infusion of FAYUVI. Symptoms may include, but are not limited to, hypotension, pyrexia, palpitation, nausea, vomiting, chills, or headache.

Closely monitor patients for clinical signs and symptoms of infusion reactions, including hypersensitivity reactions, and monitor vital signs during and after completion of FAYUVI infusion as clinically indicated. In the event of an infusion reaction during administration, pause the infusion and provide supportive care according to clinical practice. If the infusion is paused and continued administration is appropriate, restart at a slower rate after the infusion reaction has resolved.

Risk of Malignancy
Malignancy may occur following treatment with FAYUVI due to potential integration of AAV vector DNA into the genome. 

In the event of a malignancy, contact Ultragenyx Pharmaceutical Inc. at
1-888-756-8657.

ADVERSE REACTIONS
The most common adverse reactions are (≥5%): liver enzyme increased (85%), vomiting (67%), abnormal behavior (56%), diarrhea (48%), pyrexia (41%), white cell count decreased (30%), Cushingoid features (30%), decreased appetite (22%), platelet count decreased (19%), anemia (19%), constipation (15%), nausea (11%), amylase increased (11%), alkaline phosphatase increase (11%), seizure (11%), hepatomegaly (11%), muscle spasticity (7%), hypokalemia (7%), gait disturbance (7%), and adrenal insufficiency (7%).

VACCINATIONS
Prior to FAYUVI administration, consider the patient’s vaccination status. Vaccines should be avoided 30 days prior to treatment with FAYUVI (and use of corticosteroids) and while on corticosteroid therapy.

PREGNANCY
There are no data on the use of FAYUVI in pregnant women.  Women who are pregnant or desire to become pregnant should not be treated with FAYUVI. A negative serum pregnancy test must be confirmed before administration of FAYUVI in females of childbearing potential.

VECTOR SHEDDING
Temporary vector shedding of FAYUVI occurs primarily through bodily fluids and waste. Advise patients and/or caregivers on proper handling of patient bodily fluids and waste, including hand hygiene after direct contact. These precautions should be followed for 3 months after FAYUVI infusion.

Report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Ultragenyx Pharmaceutical Inc. at 1-888-756-8657.
Please see the full Prescribing Information for FAYUVI.

About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved medicines and treatment candidates aimed at addressing diseases with high unmet medical need and clear biology, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company’s website at: www.ultragenyx.com.

Forward-Looking Statements and Use of Digital Media
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the commercial launch, availability, timing of shipment and market acceptance of FAYUVI; Ultragenyx’s ability to supply FAYUVI to Qualified Treatment Centers; patient access to FAYUVI, including insurance coverage and reimbursement; the safety, efficacy, durability and potential benefits of FAYUVI; the potential commercial opportunity for FAYUVI; and Ultragenyx’s ability to satisfy FDA requirements and maintain approval for FAYUVI, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks and uncertainties related to the commercial launch and market acceptance of FAYUVI; the ability to identify eligible patients and establish and support a network of Qualified Treatment Centers; uncertainty related to insurance coverage and reimbursement; risks related to serious or undesirable side effects, including risks associated with AAV gene therapy; manufacturing risks and the ability to manufacture and supply FAYUVI in sufficient quantities and in compliance with regulatory requirements; the risk that the FDA may modify the approved indication, impose additional requirements or withdraw approval if applicable requirements are not satisfied; smaller than anticipated market opportunities; competition from other therapies or products; product liability; regulatory scrutiny; and other matters that could affect the availability or commercial potential of Ultragenyx’s products and product candidates. Ultragenyx undertakes no obligation to update or revise any forward-looking statements.

For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Ultragenyx in general, see Ultragenyx’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 5, 2026, and its subsequent periodic reports filed with the SEC.

In addition to its SEC filings, press releases and public conference calls, Ultragenyx uses its investor relations website and social media outlets to publish important information about the company, including information that may be deemed material to investors, and to comply with its disclosure obligations under Regulation FD. Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx’s Investor Relations website (https://ir.ultragenyx.com/) and LinkedIn website (https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-/).

Ultragenyx Contacts

Investors
Joshua Higa
ir@ultragenyx.com

Media
Jess Rowlands
media@ultragenyx.com

RENO, Nev., Sept. 17, 2026 (GLOBE NEWSWIRE) — Atlantis Casino Resort Spa is proud to announce that five of its restaurants have earned the 2026 Tripadvisor Travelers’ Choice Award, recognizing them among the top 10% of restaurants worldwide.

The winning restaurants are:

  • Atlantis Steakhouse
  • Oyster & Sushi Bar on the Sky Terrace
  • Red Bloom
  • Manhattan Deli
  • Purple Parrot

The five honorees represent the breadth of Atlantis’ culinary offerings, spanning fine dining, fresh seafood and sushi, Asian cuisine, classic deli favorites, and casual dining.

“We are incredibly proud to see five of our restaurants recognized by Tripadvisor travelers,” said Chira Pagidi, Corporate Director of Food and Beverage. “This recognition reflects the passion and dedication of our chefs, managers and service teams, who consistently strive to deliver exceptional food, service, and memorable dining experiences for our guests. From fine dining and fresh seafood to casual favorites, we are proud to offer memorable culinary experiences that continue to earn the trust and appreciation of visitors from around the world. Having five distinct restaurants recognized is especially meaningful, as it reflects the strength and diversity of our culinary program throughout the resort.”

The Tripadvisor Travelers’ Choice Awards recognize businesses that consistently earn excellent reviews from travelers around the world and rank among the top-rated hospitality destinations on the platform. They are based entirely on authentic guest feedback collected on Tripadvisor over a 12-month period, making the recognition a meaningful reflection of customer satisfaction and dining excellence.

About Atlantis Casino Resort Spa

Atlantis Casino Resort Spa, owned and operated by Monarch Casino & Resort, Inc. (Nasdaq: MCRI), is an award-winning luxury resort that has consistently ranked as the #1 Reno resort on TripAdvisor, earned top recognition from leading travel and hospitality organizations including U.S. News & World Report and Forbes Travel Guide, and holds the prestigious AAA Four Diamond designation. Located at the base of the Sierra Nevada, Atlantis is close to Lake Tahoe, breathtaking hiking trails, world-class skiing and premier golf courses. The property is known for its luxurious accommodations, award-winning dining experiences including Reno’s only Forbes Four-Star restaurant and Forbes Four-Star spa, captivating bars and lounges, and casino-wide action. For more information, visit www.atlantiscasino.com.

CONTACT: Media Contact

Evan Haddad
Corporate Manager of Communications and Public Relations
775-313-3873
ehaddad@atlantiscasino.com

  • The center will be a hub for Roche and Genentech, bringing together expertise in Cardiovascular, Renal and Metabolism, as well as for data science and AI specialists to drive innovation in drug discovery and development
  • It will expand Roche’s and Genentech’s presence in Boston, reflecting a long-term commitment to one of the world’s leading life sciences hubs
  • This is part of Roche and Genentech’s USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon

Basel, 17 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the grand opening of the Roche Genentech Innovation Center Boston, expanding Roche and Genentech’s US research presence in one of the world’s leading life sciences communities.

Located at Harvard’s Enterprise Research Campus in Allston, the Roche Genentech Innovation Center Boston will serve as Roche’s Cardiovascular, Renal and Metabolism (CVRM) hub, establishing a significant end-to-end R&D presence in CVRM.

With the new center, Roche and Genentech are expanding their footprint within the Greater Boston innovation ecosystem, leveraging local talent and anchoring an entrepreneurial hub at Harvard’s Enterprise Research Campus. It brings together scientists from across discovery research, clinical development, artificial intelligence and data science disciplines, and creates an end-to-end research environment spanning early-stage discovery through late-stage clinical development.

The Innovation Center is part of Roche and Genentech’s investment commitment in US manufacturing and R&D and builds on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon. Together, these investments expand an end-to-end US footprint spanning research, development and manufacturing and reflect the companies’ long-term commitment to American scientific innovation. Roche and Genentech have around 25,000 employees in the United States, with 15 R&D centers and 13 manufacturing sites across Pharma and Diagnostics.

Thomas Schinecker, CEO Roche Group:
“Scientific innovation has always been the foundation of Roche and Genentech’s success, and the United States remains one of our most important innovation hubs. This investment in Boston is an important part of our commitment to expand our US manufacturing and R&D footprint. By investing in scientific talent, new capabilities and infrastructure, we are strengthening our ability to discover and develop the next generation of medicines for patients.”

Maura Healey, Governor of Massachusetts:
“Massachusetts leads the world in life sciences because we bring together the best researchers, workers, universities and companies to solve big challenges and improve people’s lives,” said Governor Maura Healey. “Roche and Genentech’s decision to expand their presence here is another powerful vote of confidence in Massachusetts and in the people who make our state a global center for discovery and innovation. We’re proud to welcome this new Innovation Center and the groundbreaking research that will help shape the future of medicine.”

Michelle Wu, Mayor of Boston
“Boston will continue to lead in life science and innovation because of the extraordinary companies that chose to bring their ideas, talent and investment to our City. We are thrilled to welcome Roche and Genentech’s new Innovation Center to Allston, which will create hundreds of jobs, drive new investment and further strengthen Boston’s life sciences ecosystem. We look forward to working together to move innovation forward and help shape the next generation of scientific innovation.”

This new investment highlights Roche’s dedication to advancing healthcare through academic and scientific collaboration in Boston’s life sciences ecosystem. These drug discovery efforts have included work to combat antibiotic resistant bacteria as well as the use of AI in cancer research to identify targeted approaches to treatment and to analyse the effectiveness of new cancer drugs in clinical trials.

Roche and Genentech have signed a 10-year lease for the 95,000 square metre center, which will have capacity for up to 500 people across research, clinical development, data science and other areas.

About the Enterprise Research Campus
Harvard’s Enterprise Research Campus, the first phase of which is underway and developed by Tishman Speyer and Breakthrough Properties, has been intentionally designed to foster innovation and collaboration. Located adjacent to Harvard’s Science and Engineering Complex and near Harvard Business School, the ERC will be a dynamic mixed-use development integrating research and laboratory space, residential buildings, a hotel, conference center, retail units, and a variety of community-centered outdoor spaces. The first phase of construction is expected to be complete in 2026.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com

Tristan Schmitz
Phone: +41 79 529 70 35
Lorena Corfas
Phone: +41 79 568 24 95

 

Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83

 

Kirti Pandey
Phone: +41 79 398 38 53
Yvette Petillon
Phone: +41 79 961 92 50

 

Irène Stephan
Phone:  +41 79 377 83 75
Albert Thottiyil
Phone: +41 79 775 66 12

Attachment

  • Air Canada’s celebrated annual list of new restaurants spotlights 30 culinary standouts ahead of the Top 10 reveal in Toronto this November.
  • Program marks silver anniversary with an expanded platform featuring regional events, a new Air Canada’s Best New Restaurants Icons hall of fame, and a cross-country dining series.
  • This year’s program invests in the future of the industry with support for emerging culinary talent

MONTRÉAL, Sept. 17, 2026 (GLOBE NEWSWIRE) — For a quarter-century, Air Canada’s Best New Restaurants has traversed coast to coast, mapping Canada’s culinary hotspots to uncover what’s new and next, establishing its place as a leading voice in food worth flying for. To celebrate 25 years as one of the nation’s longest-running national new restaurant rankings, the airline is honouring the culinary legends who shaped modern Canadian food culture while investing directly in the industry’s next generation. That journey begins today with the reveal of the 30 finalists for 2026.

Air Canada's celebrated annual list of new restaurants spotlights 30 culinary standouts ahead of the Top 10 reveal in Toronto this November.

The Next Great Plates: The 2026 Best New Restaurants

This year’s finalists reflect the diversity, breadth and creative energy of Canada’s dining scene. Selected independently by a panel of culinary tastemakers with eyes and appetites across the country, and in collaboration with DINR, the nominated restaurants opened between May 1, 2025, and April 30, 2026, and were recognized for the quality of their food and service, as well as their contribution to Canada’s evolving culinary culture. The top 30 are:

  • 3 Pierres 1 Feu, Montréal, QC
  • Alfred’s, Revelstoke, BC
  • Angela Pastificio, Vancouver, BC
  • Antheia, Ottawa, ON
  • Antylia, Toronto, ON
  • Bar Eugenie, Toronto, ON
  • Bar Les Incompetents, St. Catharines, ON
  • Bistrot Fortune, Montréal, QC
  • Coquette, Sainte-Anne-de-Beaupré (Quebec City), QC
  • Hana Korean Steakhouse, Montréal, QC
  • Kavita, Vancouver, BC
  • Liliana, Toronto, ON
  • LORE, Collingwood, ON
  • Lumache, Victoria, BC
  • MacTaverne, Val-David, QC
  • N.L. Ginzburg, Toronto, ON
  • Nui, Vancouver, BC
  • OLDESEOUL TAVERN, Toronto, ON
  • Penny Crown, Calgary, AB
  • Radici Project, Toronto, ON
  • Restaurant Capelin, Niagara Region, ON
  • Revé, Niagara Region, ON
  • Rita Trattoria, Edmonton, AB
  • SAMMARCO, Toronto, ON
  • Seahorse, Toronto, ON
  • Snack Haüs, Winnipeg, MB
  • Sushi Jun, Calgary, AB
  • Touk, Vancouver, BC
  • Yakitori Hibahihi, Montréal, QC
  • Zia’s Place, Toronto, ON

The full list of 2026 finalists is available here.

The restaurants have been invited to join DINR, where they will be featured as Air Canada Best New Restaurant finalists. A collaborator of the program, DINR showcases Canada’s top culinary destinations and offers guests exclusive reservation access, original editorial content, and entry to sought-after culinary events.

“For 25 years, Air Canada has celebrated the people and plates defining Canadian dining,” said Andy Shibata, Vice President, Brand at Air Canada. “This year isn’t just about looking back at the icons who transformed our food culture; it’s about fuelling the future. From the 30 standout finalists on this year’s list to the young aspiring chefs entering the kitchen for the first time, we’re proud to back the talent, diversity, and creativity driving Canadian dining forward.”

Celebrating the Chefs Defining Canadian Cuisine

Air Canada’s Best New Restaurants has served as a celebrated national launchpad, bringing now-legendary dining destinations to the forefront of Canadian culture. To celebrate this rich heritage, the Air Canada’s Best New Restaurants Icons will be named — a prestigious hall of fame honouring influential chefs that first gained national recognition through the program. The inaugural class of honourees will be announced at the Top 10 celebration in November. Earlier this year, Air Canada also launched its searchable guide to every finalist since 2002, helping diners discover restaurants that remain at the heart of Canadian communities.

Setting the Table for Coast-to-Coast Culinary Collaborations
Beyond the annual ranking, the program brings these culinary stories directly to tables across the country through experiences designed for Canadian diners. First, the Air Canada’s Best New Restaurants Dining Series, Presented by DINR, will feature exclusive, one-night-only collaborations between celebrated program alumni, connecting chefs from across the country to create never-before-seen menus and unique experiences. Second, Air Canada is partnering with leading culinary festivals, to feature honoured culinary talent in exclusive curated events and custom menus.

On the Menu: Supporting the Next Gen of Canadian Culinary Talent
In partnership with the Air Canada Foundation, the Air Canada’s Best New Restaurants program is investing in the industry’s future with a $25,000 contribution to La Tablée des Chefs’ national Kitchen Brigades program. Through culinary education and industry exposure, the program helps high school students build cooking skills, teamwork, leadership, and creativity while discovering new foods and developing healthy eating habits, while supporting the continued strength of Canada’s restaurant industry. With this new additional funding, the combined support of Air Canada and the Air Canada Foundation for La Tablée des Chefs now exceeds $500,000, helping young people develop food literacy and culinary skills while supporting a strong and sustainable future for Canada’s culinary sector.

The 2026 program reaches its final course on November 16 in downtown Toronto, where Air Canada will reveal this year’s Top 10 Best New Restaurants. The marquee event will bring together the restaurants named to the 2026 longlist, media, food lovers, VIPs and the chefs behind some of Canada’s leading dining destinations. Together, they will toast this year’s top new restaurants and celebrate 25 years of culinary excellence.

For more information on the 2026 program, please visit enroute.aircanada.com.

About Air Canada

Air Canada is Canada’s largest airline, the country’s flag carrier and a founding member of Star Alliance, the world’s most comprehensive air transportation network. Headquartered in Montréal, Air Canada provides scheduled service directly to more than 180 airports in Canada, the United States and internationally on six continents. It holds a Four-Star ranking from Skytrax. Air Canada’s Aeroplan program is Canada’s premier travel loyalty program, with more than 10 million members worldwide. Members can earn or redeem points on the world’s largest airline partner network of more than 50 airlines, plus through an extensive range of merchandise, hotel and car rental partners. Through Air Canada Vacations, it offers a selection of vacation and Flight & Hotel packages, tours, cruises, car rentals, and experiences. Its freight division, Air Canada Cargo, provides air freight lift and connectivity to hundreds of destinations across six continents using Air Canada’s passenger and freighter aircraft. Air Canada’s climate-related ambition includes a long-term aspirational goal of net-zero greenhouse gas emissions by 2050. For additional information, please see Air Canada’s TCFD disclosure. Air Canada shares are publicly traded on the TSX (AC).

Contacts:        media@aircanada.ca

Internet:        aircanada.com/media

Read our annual report Here

Sign up for Air Canada news: aircanada.com

Media Resources:
Photos
Videos
B-Roll
Articles

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/e3621d60-c743-4c60-a9b2-5c378f6019bd

Caramel Apple ChataCoffee™, Pumpkin Pie Mini Churros and Red & Green Chile Cheesy Enchilada Double Chicken Bowls all available for a limited time

El Pollo Loco’s Caramel Apple ChataCoffee

El Pollo Loco's Caramel Apple ChataCoffee
El Pollo Loco’s Caramel Apple ChataCoffee

COSTA MESA, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) —  El Pollo Loco, the leading fire-grilled chicken restaurant chain, today announced a new lineup of limited-time offerings designed to bring bold, seasonal flavor to menu categories old and new. The lineup spans beverages, desserts and entrées, giving guests fresh reasons to visit any time of day.

The new LTO items include:

  • Caramel Apple ChataCoffee™ — El Pollo Loco’s classic Mexican-style horchata and iced coffee, layered with seasonal sweet and buttery caramel apple syrup, with the option to top it with a layer of creamy cold foam.
  • Pumpkin Pie Mini Churros — Perfectly crispy on the outside with a creamy pumpkin pie filling inside, finished with a dusting of cinnamon sugar.
  • Cheesy Enchilada Double Chicken Bowl — A double portion of fire-grilled chopped chicken, seasoned rice, savory pinto beans and a double portion of shredded Jack cheese, topped with handmade guacamole, cool sour cream and freshly prepared salsa fresca, and served with guests’ choice of red or green chile enchilada sauce.

New items are available for a limited-time at participating locations, beginning September 24. Loco Rewards Members will get early access to the Cheesy Enchilada Double Chicken Bowls and Caramel Apple ChataCoffee™ on September 22. Not a Loco Rewards Member? Sign up today!

“We’re always looking to layer bold, craveable flavor into every part of our menu, in a way that’s uniquely El Pollo Loco,” said Rene Pisciotti, Sr. Director of Culinary Innovation, El Pollo Loco. “These new menu items showcase the flavors our guests love in unexpected ways, from the warmth of cinnamon and pumpkin to the richness of caramel apple, all built on the same quality we’re known for.”

The new items also reflect El Pollo Loco’s broader strategy of expanding into new dayparts and menu categories to attract new guests.

“Introducing menu items like our ChataCoffee line and indulgent desserts allow us to broaden our appeal with existing and new customers,” said Liz Williams, CEO of El Pollo Loco. “By innovating across categories, from beverages and desserts to bigger, craveable bowls, we’re delighting guests beyond a traditional lunch or dinner visit.”

The Caramel Apple ChataCoffee™, Pumpkin Pie Mini Churros and Cheesy Enchilada Double Chicken Bowl are available for a limited time at participating El Pollo Loco locations nationwide, in restaurants and via the El Pollo Loco app and website for pickup and delivery.

About El Pollo Loco
El Pollo Loco (Nasdaq: LOCO) is the nation’s leading fire-grilled chicken restaurant known for its craveable, flavorful, and better-for-you offerings. Named by USA Today 10 Best Reader’s Choice Awards as a “Best Restaurant for Quick, Healthy Food” three years in a row, our menu features innovative meals with Mexican-inspired flavors made daily in our restaurants using quality ingredients. At El Pollo Loco, inclusivity is at the heart of our culture. Our community of over 4,000 employees reflects our commitment to creating a workplace where everyone has a seat at our table. Since 1980, El Pollo Loco has successfully expanded its presence, operating more than 500 company-owned and franchised restaurants across ten U.S. states: Arizona, California, Colorado, Idaho, Louisiana, Nevada, New Mexico, Texas, Utah, and Washington. The company has also extended its footprint internationally, with licensed restaurant locations in the Philippines. For more information or to place an order, visit the Loco Rewards app or ElPolloLoco.com. Follow us on Instagram, TikTok, Facebook, or X.

CONTACT:
media@elpolloloco.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e0e84a08-310d-43c6-8c13-716a61bd9794

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.